EMA Authorised: Blitzima (rituximab) — Celltrion Healthcare Hungary Kft.

View source ↗

Summary

EMA authorized Blitzima (rituximab) from Celltrion Healthcare Hungary Kft. for non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Blitzima (rituximab)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, Chronic, B-Cell. MAH: Celltrion Healthcare Hungary Kft.. Decision date: 25/09/2025